Share this page: More

Eric L. Nuermberger, M.D.

Eric L. Nuermberger, M.D.
Associate Professor of Medicine, Division of Infectious Diseases, Department of Medicine 

Eric Nuermberger, M.D.
Read Complete CV.
Email Dr. Nuermberger

My primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials. A major goal is to identify new agents that can be combined with existing drugs to shorten the duration of TB therapy or allow more intermittent drug administration.

I am also working with an innovative flow-controlled in vitro pharmacodynamic system to gain a better understanding of the pharmacodynamics of drug efficacy and selection of drug-resistant mutants during exposure to currently used agents. 

My secondary interest is the experimental chemotherapy of pneumonia caused by Streptococcus pneumoniae, the leading cause of community-acquired pneumonia in humans. The work uses a novel low-dose aerosol infection model that produces an isolated pneumonia in mice. This model may be particularly useful for evaluating the efficacy of antimicrobials that concentrate in the lung parenchyma relative to serum.


To read some of these publications online, click here . Please note that to read the full text of some of these articles requires that you have an online subscription to the journal.

1: Yew WW, Nuermberger E. High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis. 2013 Jul;17(7):853-4. doi: 10.5588/ijtld.13.0301.  PMID: 23743304.

2: Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC. Potent rifamycin-sparing regimen cures Guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3.  PMID: 23733473;  PMCID: PMC3719725.

3: Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis. Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC.  PMID: 23593945.

4: Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL; AGEDD Adult Pneumococcal Burden Study Team, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratalà J, Chang FY, Charles PG, Diaz AA, Domínguez J,  Ehara N, Endeman H, Falcó V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek  V, Kozlov RS, Lauderdale TL, Mareković I, Masiá M, Matta MA, Miró Ò, Murdoch DR,  Nuermberger E, Paolini R, Perelló R, Snijders D, Plečko V, Sordé R, Strålin K, van der Eerden MM, Vila-Corcoles A, Watt JP. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273. doi: 10.1371/journal.pone.0060273. Epub 2013 Apr 2.  PMID: 23565216;  PMCID: PMC3615022.

5: Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, Grosset JH. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis. 2013;7(2):e2085. doi: 10.1371/journal.pntd.0002085. Epub 2013 Feb 28.  PMID: 23469308;  PMCID: PMC3585034.

6: Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH. Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12.  PMID: 23341430;  PMCID: PMC3553677.

7: Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR Jr, Grosset JH. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian J Med Res. 2012 Nov;136(5):808-14.  PMID: 23287128;  PMCID: PMC3573602.

8: Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11. doi: 10.1073/pnas.1214188109. Epub 2012 Sep 10.  PMID: 23012453; PMCID: PMC3479555.

9: Dooley KE, Mitnick C, Degroote MA, Obuku E, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E; Efficacy Subgroup, RESIST-TB. Reply to Seddon, Schaaf, and Hesseling. Clin Infect Dis. 2013 Jan;56(1):168-9. doi: 10.1093/cid/cis820. Epub 2012 Sep 18.  PMID: 22990846.

10: Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli  K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.  Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/ Epub 2012 Aug 30. Review.  PMID: 22940006.

11: Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L,  Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect  Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.  PMID: 22850121.

12: Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL; Efficacy Subgroup, RESIST-TB. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013 May 1;207(9):1352-8. doi: 10.1093/infdis/jis460. Epub 2012 Jul 17. Review.  PMID: 22807518;  PMCID: PMC3693592.

13: Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. N  Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478.  PMID: 22670908.

14: Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.  PMID: 22664964;  PMCID: PMC3421552.

15: Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E; Efficacy Subgroup, RESIST-TB. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis. 2012 Aug;55(4):572-81. Epub 2012 May 21. Review.  PMID: 22615332;  PMCID: PMC3520382.

16: Chang KC, Nuermberger EL. 2011: the year in review. part I: tuberculosis. Int J Tuberc Lung Dis. 2012 Jun;16(6):740-8. doi: 10.5588/ijtld.12.0139. Review.  PMID: 22613685.

17: Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset  JH, Karakousis PC. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2012 Jul;56(7):3726-31. doi: 10.1128/AAC.00500-12. Epub 2012 Apr 30.  PMID: 22547623;  PMCID: PMC3393407.

18: Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012 May;91(5):881-8. doi: 10.1038/clpt.2011.323.  PMID: 22472995.

19: Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12. Epub 2012 Apr 2.  PMID: 22470112;  PMCID: PMC3370712.

20: Zhang T, Li SY, Nuermberger EL. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS  One. 2012;7(1):e29774. doi: 10.1371/journal.pone.0029774. Epub 2012 Jan 11.  PMID: 22253776;  PMCID: PMC3256174.

21: Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis. 2012 Feb 15;205(4):595-602. doi: 10.1093/infdis/jir786. Epub 2011 Dec 23.  PMID: 22198962;  PMCID: PMC3266133.

22: Converse PJ, Nuermberger EL, Almeida DV, Grosset JH. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101. Review.  PMID: 22004037;  PMCID: PMC3243445.

23: Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11. Epub 2011 Sep 19.  PMID: 21930883;  PMCID: PMC3232786.

24: Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2011 Sep 15;184(6):732-7. doi: 10.1164/rccm.201103-0397OC. Epub 2011 Jun 9.  PMID: 21659613;  PMCID: PMC3208599.

25: Ahmad Z, Fraig MM, Pinn ML, Tyagi S, Nuermberger EL, Grosset JH, Karakousis PC. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother. 2011 Jul;66(7):1560-6. doi: 10.1093/jac/dkr188. Epub 2011 May 20.  PMID: 21602551;  PMCID: PMC3112031.

26: Converse PJ, Almeida DV, Nuermberger EL, Grosset JH. BCG-mediated protection  against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis. 2011 Mar 15;5(3):e985. doi: 10.1371/journal.pntd.0000985.  PMID: 21423646;  PMCID: PMC3057947.

27: Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA,  Nuermberger EL, Grosset JH. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. doi: 10.1164/rccm.201012-1949OC. Epub 2011 Feb 17.  PMID: 21330452;  PMCID: PMC3114054.

28: Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother. 2011 Apr;55(4):1527-32. doi: 10.1128/AAC.01524-10. Epub 2011 Jan 31.  PMID: 21282447;  PMCID: PMC3067197.

29: Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, Nuermberger EL. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother. 2011 Apr;55(4):1781-3. doi: 10.1128/AAC.01514-10. Epub 2011 Jan 31.  PMID: 21282421;  PMCID: PMC3067133.

30: Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis. 2011 Jan 4;5(1):e933. doi: 10.1371/journal.pntd.0000933.  PMID: 21245920;  PMCID: PMC3014976.

31: Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother. 2011 Jan;55(1):56-61. doi: 10.1128/AAC.01260-10. Epub 2010 Nov 15.  PMID: 21078940;  PMCID: PMC3019670.

32: Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. doi: 10.1128/AAC.00849-10. Epub 2010 Oct 11.  PMID: 20937781;  PMCID: PMC3019674.

33: Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother. 2010 Oct;65(10):2172-5. doi: 10.1093/jac/dkq277. Epub 2010 Aug 6.  PMID: 20693172;  PMCID: PMC2941674.

34: Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology. 2010 Jul;15(5):764-78. doi: 10.1111/j.1440-1843.2010.01775.x. Epub 2010 Jun 4. Review.  PMID: 20546189.

35: Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR. The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models. PLoS One. 2010 Apr 21;5(4):e10289. doi: 10.1371/journal.pone.0010289.  PMID: 20422019;  PMCID: PMC2858211.

36: Zhang T, Bishai WR, Grosset JH, Nuermberger EL. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother. 2010 Jul;54(7):2806-13. doi: 10.1128/AAC.00400-10. Epub 2010 Apr 26.  PMID: 20421401;  PMCID: PMC2897272.

37: Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother. 2010 Apr;65(4):729-34. doi: 10.1093/jac/dkq007. Epub 2010 Jan 31.  PMID: 20123722;  PMCID: PMC2837551.

38: Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment.  Antimicrob Agents Chemother. 2009 Nov;53(11):4879-84. doi: 10.1128/AAC.00789-09.  Epub 2009 Sep 8.  PMID: 19738022;  PMCID: PMC2772305.

39: Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.  PMID: 19729664;  PMCID: PMC2784419.

40: Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JH, Karakousis PC. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis. 2009 Oct 1;200(7):1136-43. doi: 10.1086/605605.  PMID: 19686043.

41: Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20.  PMID: 19620331;  PMCID: PMC2764177.

42: Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009 Aug  15;180(4):371-6. doi: 10.1164/rccm.200904-0611OC. Epub 2009 Jun 11.  PMID:  19520903.

43: Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.  PMID:  19406981.

44: Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, Allen SS, Grosset JH, Jain SK, Lamichhane G, Manabe YC, McMurray DN, Nuermberger EL, Bishai WR. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun. 2009 Mar;77(3):1230-7. doi: 10.1128/IAI.01117-08. Epub 2008 Dec 22.  PMID: 19103767;  PMCID: PMC2643651.

45: Nuermberger E, Mitchison DA. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med. 2009 Jan  1;179(1):2-3. doi: 10.1164/rccm.200808-1333ED.  PMID: 19098156.

46: Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.  PMID: 19075058;  PMCID: PMC2663111.

47: Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S65-74. doi: 10.1016/S1472-9792(08)70037-4. Review.  PMID: 18762154.

48: Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med. 2008 Oct;29(5):542-51. doi: 10.1055/s-0028-1085705. Epub 2008 Sep 22. Review.  PMID: 18810687.

49: Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE. Repeated administration of high-dose intermittent rifapentine reduces  rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother.  2008 Nov;52(11):4037-42. doi: 10.1128/AAC.00554-08. Epub 2008 Sep 2.  PMID: 18765687;  PMCID: PMC2573112.

50: Subramanian AK, Nuermberger EL. Tuberculosis in transplant recipients: diagnostic and therapeutic dilemmas. Transpl Infect Dis. 2008 Jul;10(4):229-30. doi: 10.1111/j.1399-3062.2008.00332.x.  PMID: 18755013.

51: Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC.  Epub 2008 Aug 21.  PMID: 18723432;  PMCID: PMC2577731.

52: Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008 Oct;52(10):3664-8. doi: 10.1128/AAC.00686-08. Epub 2008 Aug 11.  PMID: 18694943;  PMCID: PMC2565869.

53: Nuermberger E. Older antibiotic gains new respect as potent treatment for tuberculosis. Rifapentine is already approved for use with humans. Home Healthc Nurse. 2008 Apr;26(4):204-5. doi: 10.1097/01.NHH.0000316691.61644.2d.  PMID: 18408506.

54: Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008 Apr;52(4):1522-4. doi: 10.1128/AAC.00074-08. Epub 2008 Feb 19.  PMID: 18285479;  PMCID: PMC2292539.

55: Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007 Dec;4(12):e344.  PMID: 18092886;  PMCID: PMC2140085.

56: Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of  tuberculosis. Antimicrob Agents Chemother. 2007 Dec;51(12):4261-6. Epub 2007 Oct  15.  PMID: 17938193;  PMCID: PMC2168018.

57: Byrne ST, Denkin SM, Gu P, Nuermberger E, Zhang Y. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol. 2007 Aug;56(Pt 8):1047-51.  PMID: 17644711.

58: Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007 Nov;51(11):4029-35. Epub 2007 May 25.  PMID: 17526760;  PMCID: PMC2151409.

59: Jain SK, Hernandez-Abanto SM, Cheng QJ, Singh P, Ly LH, Klinkenberg LG, Morrison NE, Converse PJ, Nuermberger E, Grosset J, McMurray DN, Karakousis PC, Lamichhane G, Bishai WR. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J Infect Dis. 2007 Jun 1;195(11):1634-42. Epub 2007 Apr 23.  PMID: 17471433.

60: Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH. Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agents Chemother. 2007 Jan;51(1):403; author reply 403-4.  PMID: 17182861;  PMCID: PMC1797700.

61: Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2006 Aug;50(8):2621-5.  PMID: 16870750;  PMCID: PMC1538692.

62: Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101. Epub 2006 Mar  30.  PMID: 16574936;  PMCID: PMC1862756.

63: Nuermberger E. Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials. Pharmacotherapy. 2005 Dec;25(12 Pt 2):134S-139S. Review.  PMID: 16305283.

64: Nuermberger E, Helke K, Bishai WR. Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy. Int J Antimicrob Agents. 2005 Dec;26(6):497-503. Epub 2005 Nov 9.  PMID: 16289711.

65: Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1452-6. Epub 2005 Sep 8.  PMID: 16151038;  PMCID: PMC1853317.

66: Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1457-62. Epub 2005 Sep 1.  PMID: 16141439;  PMCID:  PMC2718441.

67: Nuermberger E, Bishai WR, Grosset JH. Latent tuberculosis infection. Semin Respir Crit Care Med. 2004 Jun;25(3):317-36.  PMID: 16088473.

68: Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005 Jun;49(6):2289-93.  PMID: 15917523;  PMCID: PMC1140529.

69: Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005 May;5(5):275-86. Review.  PMID: 15854883.

70: Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005 Jan 1;40(1):100-7. Epub 2004 Dec 7.  PMID: 15614698.

71: Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, Bishai WR. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med. 2004 Sep 6;200(5):647-57.  PMID: 15353557;  PMCID: PMC2212740.

72: Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004 Nov 15;170(10):1131-4. Epub 2004 Aug 11.  PMID: 15306535.

73: Nuermberger EL, Bishai WR. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin Infect Dis. 2004 May 15;38 Suppl 4:S363-71.  PMID: 15127371.

74: Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):243-55. Epub 2004 Mar 13. Review.  PMID: 15024625.

75: Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary  tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun. 2004 Feb;72(2):1065-71.  PMID: 14742554;   PMCID: PMC321637.

76: Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis. 2004 Jan 1;38(1):99-103. Epub 2003 Dec 8. Review.  PMID: 14679455.

77: Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6. Epub 2003 Oct 24.  PMID: 14578218.

78: Nuermberger EL, Bishai WR. Significance of macrolide resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2003 Sep;52(3):524-5; author reply 525. Epub 2003 Jul 29.  PMID: 12888594.

79: Lanzkron S, Moliterno AR, Norris EJ, Gould SA, Segal J, Nuermberger EL, Ness  PM. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion. 2002 Nov;42(11):1422-7.  PMID: 12421214.

80: Nuermberger E. Current concepts in HIV-associated nephropathy. Hopkins HIV Rep. 1999 Sep;11(5):12-4.  PMID: 12182132.

81: Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother. 2002 Jun;46(6):1875-9.  PMID: 12019103;  PMCID: PMC127203.

82: Myers JS, Nuermberger E. Cases from the Osler Medical Service at Johns Hopkins University. Diagnosis: Polymorphic population of mature and immature hematopoietic cells consistent with extramedullary hematopoiesis. Am J Med. 2002  Apr 15;112(6):494-5.  PMID: 11959062.

83: Nuermberger E. Cases from the Osler medical service at Johns Hopkins university. Am J Med. 2002 Jan;112(1):70-1.  PMID: 11812410.

84: Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000 Sep;58(3):1253-60.  PMID: 10972688.